Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
74 hedge funds and large institutions have $270M invested in Avadel Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 16 closing their positions.
67.42% more ownership
Funds ownership: 0% → 67.42% (+67%)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
3% less funds holding
Funds holding: 76 → 74 (-2)
6% less capital invested
Capital invested by funds: $286M → $270M (-$15.9M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$9.97M |
| 2 |
BlackRock
New York
|
+$5.44M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.26M |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.88M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$5.97M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.12M |
| 3 |
KFA
Kelleher Financial Advisors
New York
|
-$2.01M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.3M |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$1.28M |
AVDL Hedge Fund Activity: Q1 2017 in Review
74 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2017, worth a combined $270M — down 5.6% from $286M a quarter earlier.
Fund positioning in AVDL was balanced in Q1 2017: 16 funds opened new positions, 16 closed out, 18 added to existing stakes and 19 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $9.97M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $5.97M sold.
- 74 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2017, down from 76 in Q4 2016.
- Funds reported $270M of Avadel Pharmaceuticals stock for Q1 2017, down 5.6% quarter-over-quarter.
- 16 funds opened new Avadel Pharmaceuticals positions in Q1 2017 and 16 closed out, a net change of 0 holders.
- The largest Avadel Pharmaceuticals buyer in Q1 2017 was J. Goldman & Co, an estimated $9.97M added.
- The largest Avadel Pharmaceuticals seller in Q1 2017 was Ghost Tree Capital, an estimated $5.97M sold.
Based on aggregated 13F filings for Q1 2017.